TRBJ1-4: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

Target Name: TRBJ1-4

NCBI ID: G28632

TRBJ1-4

Other Name(s): TCRBJ1S4 | TRBJ14 | T cell receptor beta joining 1-4

TRBJ1-4: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

TRBJ1-4 (Tumor-associated Extracellular RNA) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and function have made it an attractive target for researchers to study and develop new treatments.

TRBJ1-4 is a smallRNA molecule that is expressed in various tissues and organs, including the brain, lung, heart, liver, and pancreas. It is characterized by its unique structure, which consists of a 19-nt stem-loop region and a 3' terminal cap structure. The stem-loop region is composed of three transcription factor binding sites (TBP), while the 3' terminal cap structure is composed of a terminal 7nt overhang and a G-rich loop.

TRBJ1-4 has been shown to play a role in various physiological processes, including cell growth, apoptosis, and inflammation. Its expression has also been linked to various diseases, including cancer. For example, TRBJ1-4 has been shown to be overexpressed in various types of cancer, including lung, breast, and colorectal cancer. This suggests that it may be a promising biomarker and drug target for these diseases.

One of the key challenges in studying TRBJ1-4 is its complex structure. The stem-loop region of TRBJ1-4 is relatively stable, which makes it difficult to study. Additionally, the 3' end cap structure is also relatively stable, which can affect the stability and function of the entire molecule. To overcome these challenges, researchers have used various techniques, such as RNA interference and CRISPR/Cas9 genome editing, to study TRBJ1-4 at the gene and protein level.

In addition to its potential as a drug target, TRBJ1-4 also has implications for cancer diagnosis and treatment. Its overexpression in various types of cancer makes it a potential biomarker for these diseases. Additionally, its expression has also been linked to the development of various types of cancer, which may provide insight into the early stages of cancer development.

In conclusion, TRBJ1-4 is a promising drug target and biomarker for various diseases, including cancer. Its unique structure and function make it an attractive target for researchers to study and develop new treatments. While further research is needed to fully understand its potential, its potential as a drug target and biomarker is a promising area of 鈥嬧?媟esearch to explore.

Protein Name: T Cell Receptor Beta Joining 1-4

Functions: J region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRBJ1-4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRBJ1-4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets